EP0318491A1 - Determination de la concentration d'analyte a l'aide de deux substances de marquage - Google Patents

Determination de la concentration d'analyte a l'aide de deux substances de marquage

Info

Publication number
EP0318491A1
EP0318491A1 EP87905234A EP87905234A EP0318491A1 EP 0318491 A1 EP0318491 A1 EP 0318491A1 EP 87905234 A EP87905234 A EP 87905234A EP 87905234 A EP87905234 A EP 87905234A EP 0318491 A1 EP0318491 A1 EP 0318491A1
Authority
EP
European Patent Office
Prior art keywords
analyte
receptor
binding sites
labelled
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP87905234A
Other languages
German (de)
English (en)
Inventor
Roger Philip Ekins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EKINS Roger Philip
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0318491A1 publication Critical patent/EP0318491A1/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements

Definitions

  • the present invention relates to a method of measur ⁇ ing the concentration of analytes in liquids using two different labelling markers by irnmunoassay or immunometric techniques, also to an analytical device and kit.
  • Background Art It is known to measure the concentration of an ana ⁇ lyte such as a drug or hormone in a liquid by exposing the liquid to a receptor having binding sites on its molecule for the analyte, separating fhe receptor contain ⁇ ing bound analyte from the liquid, measuring a value representative of the proportion of the available binding sites on the receptor molecule that have been occupied by analyte molecules (referred to as the fractional occu ⁇ pancy) and comparing that value with a corresponding measured value obtained with a solution of known concen- tration of the analyte.
  • the measurement of the value in question can be achieved by a back-titration technique involving contact ⁇ ing the receptor molecule containing bound analyte with a labelled version of the analyte. It is also possible to use, instead of labelled analyte, another labelled material able to occupy only those of the analyte binding sites on the receptor molecule that are not actually occupied by the .analyte itself. These two systems are called competitive systems because the labelled analyte or other labelled material competes with the analyte being measured to occupy binding sites on the receptor molecule.
  • the back-titration technique involves contacting the receptor molecule con ⁇ taining bound analyte with a material able to bind with the bound analyte or with only the binding sites occupied by bound ar.r.lyte, this material being itself labelled or being subsequently labelled by attachment of a labelled marker.
  • This system is known as a non-competitive system because there is no competition for binding sites.
  • the back-titration reagent (analyte or other r ⁇ ater- ial) is labelled with a marker.
  • markers have been used, for example radioactive isotopes (radio- immunoassay) , enzymes, chemiluminescent substances and fluorescent markers ( fluoroimmunoassay) , the latter being either a conventional fluorescent material such as fluor- escein or a material which becomes fluorescent only on activation and estimation by time-resolved pulse fluor ⁇ escence such as a europium or other lanthanide chelate, the magnitude of the fluorescence as revealed on scanning with a high-intensity light beam of appropriate wavelength being a measure of the amount of the labelled material taken up by the receptor molecule containing bound analyte.
  • Hitherto known assay techniques have depended either on a precise knowledge of the total amount of the receptor present in each sample or on the knowledge that the amount of the receptor remains precisely the same from sample to sample, especially from the unknown sample to the standard samples used for calibration purposes. They have also required an exact knowledge of the total sample volume. These requirements derive from the fact that the measured signal (e.g. fluorescence) in such systems is representative of the total amount of labelled material bound and, provided that not all the labelled material has been bound (in which event the system would be un ⁇ responsive to changes in the amount of analyte present), this total amount is dependent not only on the fractional occupancy of the binding sites on the receptor molecule, but also on the amount of receptor molecule present.
  • the measured signal e.g. fluorescence
  • the fluorescent signal emitted in hitherto- known fluoroimmunoassay techniques has invariably depended in a complex (and, in practice, unknown) manner on the amount of receptor molecule used in the system and on the total amount of analyte present; this implies that both the amount of receptor and the sample volume used must be carefully standardised to ensure correct esti ⁇ mates of the analyte concentration in the test sample, such standardisation being a characteristic and essential feature of all hitherto-known fluoroimmunoassay techniques, particularly those described as competitive as defined above.
  • the fractional occupancy of the antibody by analyte is itself dependent on the amount of receptor present; for example, increasing the number of receptor molecules by a given factor also increases the number of analyte molecules which it binds, but by a very different factor, causing the fractional occupancy of the receptor to markedly change.
  • the amount of the labelled material binding to the receptor will also increase, but likewise in a non-proportional manner.
  • a fluorescent label on the receptor molecule and a fluorescent label on the labelled (competing) ligand are detected quanti- tatively while they are bound to each other and the quan ⁇ tity of the analyte present in an unknown sample is deter ⁇ mined as a function of the ratio of the quantitative measurements of the two labels. It is evident from the disclosures in WO/80/02076 that, apart from the use of a second label, the immuno- assays described are conducted in a conventional manner.
  • WO 80/02076 thus merely provide a crude means of approximately correcting for minor vari ⁇ ations in the amount of receptor present in assay systems of this type as described above, and are restricted in their application to this purpose.
  • the ratio of the quantitative measurements of the two labels can be demonstrated, both theoretically and experimentally, not generally to constitute a measure of the amount of analyte in a conventional receptor-based assay system (such as an immunoassay), and the use of this ratio as a response variable will therefore generally give rise to analyte measurements which are grossly in error.
  • WO 80/02076 offer a tech ⁇ nique (of limited usefulness) for simultaneously monitor- ing (and approximately correcting for) small variations in the amount of receptor present in individual sample incubation tubes as discussed above, they do not describe the design and operation of assay systems in which the measured ratio of two labels is an accurate -and reliable measure of the analyte concentration in the sample.
  • WO 80/02076 provide at most the means of approximately correcting for a. small variations in the amount of receptor used in receptor-based assays and b. small, short term, vari ⁇ ations in the signal detection efficiency of label-meas ⁇ uring equipment. These corrections are of questionable validity and restricted utility, and have not, for these reasons, been adopted in routine assay practice. Summary of Invention
  • My present invention relates to receptor assays of completely different concept and design from those envis ⁇ aged or described in WO 80/02076, and in which the frac ⁇ tional occupancy of the receptor is a true, accurate and reliable measure of the a ' nalyte concentration in the medium (irrespective of the total amounts of receptor and or analyte present).
  • These systems (not referred to nor visualised in WO 80/02076) necessarily and specific ⁇ ally depend on measurement of the fractional analyte occupancy of the receptor, i.e. on measurement of the ratio of unoccupied (or occupied) to total receptor sites (or some essentially equivalent ratio, e.g. the unoccupied/occupied site ratio), and therefore desirably require the separate labelling of these two classes of site.
  • these systems require that the relative amounts of receptor and analyte, and the affinity between them,are such that the introduction of the receptor into the test sample has no significant effect on; the concentration therein of the analyte.
  • I provide a method of determining the concentration of - an analyte in an unknown liquid sample comprising contact ⁇ ing the sample with a receptor having binding sites on its molecule for the analyte and labelled with a first marker, whereby a fraction of the binding sites on the receptor molecule become occupied by the analyte, back- titrating the receptor having fractionally occupied bind ⁇ ing sites by means of a back-titration technique involving a system including a second marker different from the first, measuring the relative strengths of the two signals produced by the two markers to provide a value repre ⁇ sentative of the fractional occupancy of the binding sites on the receptor molecule by the analyte, and compar- ing that value with one or more corresponding values obtained in the same way using one or more standard liquid samples of known analyte concentration, characterised in that the unknown and standard liquid samples are each contacted with such a -small amount of the receptor, having regard to its affinity constant with the analyte
  • I mean a fraction sufficiently small that the errors introduced by permitting a change in the initial analyte concentration are as small as, or smaller than, the errors unavoidably introduced into the measuring pro ⁇ cedure elsewhere by limitations in the accuracy of sample and reagent manipulation, signal measurement, standardisa ⁇ tion, temperature variation and the like.
  • errors customarily amount (in total) to 10% or less, and the binding of 5% or less of the total ana ⁇ lyte in test samples would therefore be likely to cause inter-sample measurement errors arising from this particu ⁇ lar source to contribute negligibly to the total.
  • this limit can sometimes be exceeded without detri ⁇ ment.
  • [A] is the concentration of the analyte in the sam ⁇ ple and K is the affinity constant of the receptor for the analyte and is a constant at a given temperature.
  • any of the known types of marker can be used, for example radio ⁇ active isotopes (for example radioactive iodine), chemi- luminescent substances, fluorescent markers and enzymes. These may be attached to the receptor molecule and the back-titration reagent in conventional ways. Both markers will usually be of the same type, although different. The markers will be quantitatively detected in a manner appropriate to their nature, for example by counting the radioactivity of a radioactive marker or scanning a fluorescent marker with a light beam, if necessary after activation. Preferably fluorescent or potentially fluorescent markers are used.
  • my invention involves the formation of labelled products as intermediates in a method accord ⁇ ing to the invention, said labelled products comprising receptor molecules labelled with a first, preferably fluorescent marker and having binding sites a proportion of which are occupied by molecules of an analyte, said proportion being fully representative of the concentration of the analyte in a sample with which the receptor mole ⁇ cules have been contacted because of the use of only a trace amount of the receptor relative to the analyte, " and a material bound either directly or indirectly to the occupied binding sites or to the unoccupied binding sites and labelled with a second, preferably fluorescent marker different from the first.
  • my invention provides a kit for use in a method of determining the concentration of an analyte in a liquid sample, said kit comprising a solid substrate having attached thereto molecules of a receptor labelled with a first, preferably fluorescent marker and having binding sites for an analyte, the amount of receptor on the substrate being selected according to the size of the liquid sample so that only an insignifi ⁇ cant fraction of the analyte in the sample becomes bound to the receptor, one or more standard solutions containing known concentrations of the analyte and a back-titration reagent labelled with a second, preferably fluorescent marker different from the first and able to bind directly or indirectly either with the bound analyte or with the binding sites occupied by the bound analyte or to bind with the binding sites not occupied by the bound analyte.
  • an extended solid substrate such as a plate or rod, bearing at a plurality of spaced-apart locations a plural ⁇ ity of receptors each having in their molecule binding sites for an analyte, the receptor at any one location having binding sites specific for an analyte different from those on receptors at one or more other locations, each of the receptor molecules being labelled with a marker or being capable of being so labelled.
  • Figure 1 illustrates schematically a competitive and non-competitive system according to the invention
  • Figure 2 is a perspective view of an analytical tool according to the invention.
  • the diagram shows a labelled receptor 1, exemplified by a first anti-analyte antibody labelled with a first fluorophor (not shown).
  • the receptor 1 has on its molecule binding sites 2, some of which are occupied by analyte molecules 3.
  • the bound analyte molecules 3 are in turn bound to a labelled material t exemplified by a second anti-analyte antibody 4 labelled with a second fluorophor (not shown).
  • the binding sites 2 on the first anti-analyte antibody 1- that are not occupied by the analyte 3 are occupied by a labelled reagent, exemplified by an anti-idiotypic antibody 5, also labelled with the second fluorophor (not shown).
  • the complete system is scanned by a laser beam 6 and the first- fluorophor emits d.-photons 7 and the second- fluorophor 'emits j ⁇ -photons 8 differentiated from the - photons by some property or effect.
  • Both c ⁇ and ⁇ 5-photon signals will be affected equally by changes in the total amount or surface density of the first anti-analyte anti ⁇ body present, provided that the fractional occupancy of binding sites is unchanged, but only the o -photon signal will be affected by changes in the fractional occupancy of the binding sites by the analyte, being increased with increasing occupancy in the non-competitive system but decreased with increasing occupancy in the competitive system.
  • the ratio of the two sig- nals is dependent on the fractional occupancy but not on the total amount of the first anti-analyte antibody.
  • My invention can be used for the estimation of any analyte for which a receptor having appropriate binding sites in its molecule is known or can be produced. It may particularly be used to estimate accurately concen ⁇ trations in the picomolar or nanomolar ranges as well as higher concentrations in the micromolar range, e.g. 10 -9 to 10-5 molar.
  • Analytes that can be estimated in this way include hormones such as thyroid hormones or steroid hormones, e.g. cortisol, vitamins, proteins and protein hormones such as insulin and gonadotrophins, viruses, drugs, poisons and other normal or abnormal components of human or animal body fluid such as blood, serum, saliva, urine or the like.
  • ana ⁇ lytes examples include WO.80/02076 mentioned above, and their concentrations may be measured by the process of the present invention. Trace contaminants such as toxins, foreign proteins and the like in foodstuffs and biological contaminants in water and other liquid media can also be estimated.
  • the analyte to be estimated may be present in a sample in equilibrium with the same analyte revers- ibly bound to a binding agent, such as endogenous binding protein, the concentration of free analyte being measured by the method of the invention.
  • the sample can be free from reversibly bound analyte, and the inven ⁇ tion can have greater importance for such measurements as the reversibly bound analyte is not available to diss ⁇ ociate and hence to buffer changes in analyte concentra- tion due to uptake by the receptor molecule.
  • the receptor used will be one having binding sites on its molecule for the analyte to be estimated. These binding sites should be essentially constant in number per molecule and should thus be chemical binding sites rather than physical adsorption sites. They should also be capable of occupation solely by the analyte as compared to any other ingredient of the samples undergoing esti ⁇ mation and will thus preferably be specific to the analyte.
  • Antibodies e.g. monoclonal antibodies, are particularly preferred receptor molecules, but enzymes specific to individual analytes are other examples of receptor mole ⁇ cules that can be used. Antibodies to a wide variety of analytes are known or described in the literature or are commercially available and other antibodies speci- fie to other hormones etc.
  • the receptor is preferably chosen with an affinity constant for the analyte such that between 25% and 75% of the binding sites on the receptor molecule are occupied by the analyte at its expected concentration in the unknown sample, i.e. it has an affinity constant from one third to 3 times the reciprocal of the expected analyte concentration.
  • Affin ⁇ ity constants for receptors may be determined by a stan- dard Scatchard analysis (Ann. N.Y. Sci., 5_1, (1949, 660).
  • the entities to be labelled for immunofluorometric or fluoroimmunoassay can be labelled either with conventional fluorescent materials such as fluoroscein or with materials usable in time- resolved pulsed fluorescence such as europium and other lanthanide chelates, see for example S. Dakubu and others, "High sensitivity pulsed-light time-resolved fluoroimmuno ⁇ assay” in "Practical Immunoassay” edited by W. Butt, Marcel Dekker Inc. (1984) at pages 71-101 and both types of material are within the term "fluorescent marker".
  • Reagents suitable for use in the back-titration tech- nique either using a competitive system, for example with an anti-idiotypic antibody or a labelled analyte, or a non-competitive system, for example with an anti-analyte antibody, are also e-ither known in the art or can be man ⁇ ufactured by conventional techniques.
  • the reagents may themselves be labelled with a marker, preferably a fluorescent marker, again of a known or conventional type using a known or conventional technique, before use or they may be reacted in situ with a further reagent which is itself labelled with such a marker.
  • the back-titration can be performed subsequently to the separation of the unbound analyte from contact with the receptor molecules (a two-step assay) or, provided that the sample volume is known, simultaneously with contact of the unbound analyte with the receptor molecules (a one-step assay):
  • the signals emitted by the two markers may be signals capable of being differentiated in various alternative ways, for example by wavelength of the emitted photons, by time decay of the fluorescence in the case of time- resolved pulsed fluorescence (both or only one of the markers showing such decay), or by polarisation.
  • the wavelengths, time-decay patterns and s ⁇ forth of a variety of marker systems are already known in the literature and others can be determined by known techniques.
  • the two markers should provide signals which are sufficiently different to enable them to be resolved by the measuring instrument.
  • the measure- ment of the ratio of the signals would necessitate the complete removal of all the labelled back-titration reagent which is not bound to the labelled receptor molecule/bound analyte system, for example using an immunoadsorbent, before the measure- ment could be effected, and such a removal step is incon ⁇ venient.
  • the labelled receptor molecules be bound as a monolayer to a solid substrate and be separated from the residual unbound analyte and the residual unbound labelled back-titration reaction present in the liquid(s) in which the assay is conducted before measurement of the signal ratio is undertaken.
  • Suitable substrates are made of glass, plastics or the like and techniques for binding receptor molecules such as antibod ⁇ ies to such surfaces are known and can be used for the purposes of this invention, see for example US Patents 4,399,217, 4,381,291, 4,357,311, 4,343,312 and 4,260,679.
  • a multi-spot device can then be used to estimate concentrations of a plurality of analytes in. a single liquid sample, separ ⁇ ate labelled back-titration reagents being provided for each different analyte such that each pair of labels is capable of being differentiated and the ratio of the strengths of the signals determined.
  • microbead 22 is formed with a plurality " of depressions or wells 21 each of a size to accommodate a microbead 22, likewise made of polystyrene or other inert material, suitably having a diameter of about 1 mm or less.
  • These beads have pre ⁇ viously been soaked in a conventional manner in solutions containing a receptor such as an antibody so as to deposit the receptor as a layer on the surface of the bead, differ ⁇ ent beads being soaked in different solutions containing different receptors, and the various receptors being chosen according to the analytes to be estimated and being optionally labelled with an appropriate marker.
  • the microbeads 22 are retained in the walls 21 by an appropriate inert adhesive such as a conventional comm ⁇ ercially available adhesive for polystyrene.
  • the microbeads 22 on the plate 20 are contacted with the sample containing analyte(s) to be estimated and then with appropriate back-titration reagents bearing appropriate labels followed by estimation of the relative signal strengths of the two markers.
  • Different markers will be chosen for different beads and back-titration reagents to enable the readings for one bead to be separ ⁇ ated from those for another or alternatively each bead will be scanned separately, the latter alternative being facilitated by the use of fluorescent or fluorogenic markers.
  • Such a device can be constructed in numerous other ways.
  • the beads 22 could be dispensed with and the receptors applied directly to the wells 21 as solutions and optionally the solvents removed leaving solid layers.
  • the beads and wells could be dispensed with and the receptors printed onto the plate surface in an appropriate manner.
  • the plate could also be re ⁇ placed by a rod or other base.
  • the number of different receptors could be as few as 2 or considerably higher, for example 5, 10 or more, and the number of different spots with the same receptor could be one or more, the use of several spots with the same receptor providing means for checking the results from a single spot.
  • the scanning light beam is preferably a high- intensity monochromatic or substantially monochromatic beam, especially a laser beam.
  • the wavelengths for the excitation of the fluorescence using the scanning light beam should be chosen according to the nature of the fluorescent markers according to known principles and it is clearly preferable for both signals to be capable of excitation by and actually to be excited by a beam of a single wavelength.
  • Pulsed fluorescence with time- resolution is the preferred technique for at least one of the markers because it enables the background inter ⁇ ference to be screened out more readily, but it is not an essential part of my invention. If other types of marker are used appropriate standard counting or esti ⁇ mating devices and methods are used instead.
  • the invention is operated using antibodies or other receptor molecules in such a small amount and of such an affinity constant for the analyte to be esti ⁇ mated that only an insignificant fraction (usually less than 5%, preferably less than 1%) of the total amount of analyte present in the sample becomes bound to the receptor molecules, it is unnecessary to use a sample of known volume for the concentration measurement or samples of constant volume for the calibration tests, nor need such volume be measured accurately or at all, provided that it is sufficiently large in relation to the amount of receptor that only an insignificant fraction of the analyte becomes bound to the receptor.
  • the device can therefore be used as a probe to monitor mixed analyte concentrations in large bulks of fluid such as are found in indystrial processes, r
  • a further advantage is that, when using fluorescent markers and scanning with a light beam, the light beam need not encompass the entire spot containing the receptor molecules but can merely sample a portion of the spot because the total amounts of bound analyte and receptor molecule need not be studied.
  • the labelled anti-idiotypic antibody or other labelled back-titration reagent should occupy all the binding sites left unoccupied by the ana ⁇ lyte, provided that it occupies a proportion of them which remains constant as between estimations using the liquid sample ⁇ f unknown analyte concentration and the standards of known analyte concentration.
  • This will in general involve the use of constant (relatively high) concentrations of anti-idiotypic antibody or other labell ⁇ ed back-titration reagent exposed to trace amounts of the receptor molecule/bound analyte system or the use of constant volumes as well as constant concentrations. Similar remarks apply to the reaction of the bound analyte the analyte-occupied binding sites in the non-competitive back-titration system.
  • the present invention can be packaged for commercial use in the estimation of analytes in hospitals and the like, in conjunction with an appropriate fluorescence- measuring instrument, in the form of a kit composed of the labelled receptor molecules on a solid substrate, standard solutions of the analyte and labelled back-titra ⁇ tion reagents. Use of such a kit will enable the measure- ments to be performed routinely on suitable instruments.
  • Antithyroxine antibody is commercially readily available, and has also been prepared in the Department of Molecular Endocrinology, the Middlesex Hospital Medical School, Mortimer Street, London, both by conventional (in vivo) immunisation techniques, " and by in vitro mono ⁇ clonal antibody production methods.)
  • the antithyroxine antibody used in this Example was a specific T4 monoclonal antibody prepared by selection from a range of antibodies produced by immunisation of mice using bovine thyro- globulin as immun ⁇ gen. It possesses a binding constant
  • T4 present in serum (1 ml) was extracted using a commercially available anion exchange resin (BioRad AGlx2 (400-600 mesh) as a column) and eluted with 70% acetic acid after washing (see Endocrinology, 117 (1985), page 1890).
  • Recovery experiments using negligible trace quantities of 125I labelled T4 initially added to the test serum) revealed total recoveries in the order of 70%.
  • Test serum eluates were each redissolved in a stan ⁇ dard Hepes buffer (50 mis) to yield T4 solutions calcu- lated as lying in the concentration range 0.5-1.5 ng/ml
  • Standard T4 solutions were made up by appropriate dilution of a stock solution of T4 in Hepes buffer to yield a range of T4 concentra ⁇ tions lying between 0 and 10 ng/ml.
  • the combined T4 concentration equalling 0.1 ng/ml, for incubation times varying from 10 minutes to
  • I-labelled T4 counted using a dual channel gamma coun ⁇ ter, and conventional calculation methods, to distinguish
  • Iactivity to incubation time and amount of labelled antibody were drawn.
  • an amount of antibody and an incubation time were selected such that in the order of 5% of the total T4 present in the incubation mixture (i.e. approximately 5 pg, yielding approximately 1000 125I cts/min) was calculated as being adsorbed by the antibody (i.e. an amount of antibody yielding approximately 200 I cts/min and a total incu ⁇ bation time of 4 hours). It was confirmed that under these conditions: a. increasing or decreasing the amount of antibody used by factors of 2 did not significantly (i.e. within 2%) change the 1251/131I ratio; b. increasing the volume of the standard solution used did not affect t .h. e 1251 ⁇ / / 131 ⁇ I ratio.
  • assay cali ⁇ bration was effected in the following manner.
  • the standard amount of antibody was incubated with 1 ml volumes of the standard T4 concentrations described above for 4 hours.
  • the solid phased antibody was then, in each case, isolated by centrifugation, briefly washed with buffer and reincubated with 3 ml volumes of a standard solution of 125I-labelled T4 containing approximately 1 ng/ml
  • Example 1 illustrates the route taken to establish a valid "dual label ratio" competitive immunoassay method.
  • T4 labelled with 125I and fluorescein
  • anti ⁇ body was coated (by adsroption) onto small polystyrene discs ⁇ rather than covalently linked to microcellulose as described in Example 1, using a well-known technique for coating polystyrene.
  • the T4 concen- tration present in the unknown samples was determined from the rhodamine/fluorescein fluorescence ratio using a Perkin Elmer Type LF-5 luminescence spectrometer (fluori- meter) to measure the fluorescence signals sequentially. The results thus obtained were again compared with those relying on measurements of the isotope ratio as described in Example 1 and with a conventional T4 assay procedure, and again satisfactory agreement obtained.
  • Example 3 Establishment of a dual fluorescence T4 assay method involving time-resolved pulse fluorescence.
  • T4 and anti-T4 antibody were labelled respectively with terbium and europium chelates with EDTA (ethylene diamine tetraacetic acid) coupled onto the antibody in a known manner.
  • EDTA ethylene diamine tetraacetic acid
  • the signal ratio was measured by known pulsed-light fluorescence techniques using a known time-resolving fluorimeter, and the results obtained with the unknown sample compared with the calibration curve obtained with standard solu ⁇ tions. Again satisfactory agreement was obtained with results obtained by other methods.
  • a kit for use in the estimation of RSH (thyrotrophin) according to the invention is composed of the following components:
  • Standard solutions contain 0.2, 1.0, 5.0, 20.0 and 100 micro-international units of TSH per mol.
  • the back-titration reagent is likewise a commer ⁇ cially available anti-TSH monoclonal antibody, this time labelled with .a europium (III) chelate with cupric tri- fluoroacetylacetone and formaldehyde in a manner similar to that proposed in published International Patent Appli ⁇ cation WO 86/01604.
  • the first antibody is permanently fluorescent and the second is capable of estimation by time-resolved pulse fluorescence.
  • Such a kit can be used for the estimation of TSH by a similar procedure to that described in Examples 1-3 above, the amount o anti-TSH antibody and the size of the sample containing TSH being chosen relative to one another so that about 5% or less of the TSH in the sample is bound to the anti-TSH antibody on the plate.
  • the back-titration involves a non-competitive system rather than a competitive system but is in principle the same.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Afin de mesurer la concentration d'un analyte dans un échantillon liquide, l'échantillon est mis en contact avec une molécule réceptrice ayant des sites de liaison de l'analyte et marquée par un premier marqueur de sorte que l'analyte occupe une partie des sites de liaison de la molécule réceptrice, l'échantillon étant mis en contact avec une quantité si réduite de molécules réceptrices, compte tenu de sa constante d'affinité avec l'analyte, que seule une partie insignifiante de l'analyte se lie aux cellules réceptrices. Les molécules réceptrices à sites de liaison en partie occupés sont titrées en retour par une technique de titrage en retour selon un système comprenant un deuxième marqueur différent du premier et la puissance relative des signaux produits par les deux marqueurs est mesurée pour donner une valeur représentative de l'occupation partielle des sites de liaison de la molécule réceptrice par l'analyte. Cette valeur est comparée avec une ou plusieurs valeurs correspondantes obtenues de la même façon à partir d'échantillons liquides standard ayant une concentration connue d'analyte. Un dispositif d'analyse utile pour appliquer ce procédé comprend un substrat solide étendu (20) portant en une pluralité d'emplacements espacés (21) une pluralité de molécules réceptrices diverses (22) ayant chacune des sites de liaison d'un analyte, la molécule réceptrice à n'importe quel emplacement ayant des sites de liaison spécifiques à un analyte différent des analytes correspondant aux sites de liaison spécifiques des autres molécules réceptrices situées aux autres emplacemnts. Chaque molécule réceptrice peut être facultativement marquée. Ce dispositif peut faire partie d'un kit d'application du procédé.
EP87905234A 1986-08-06 1987-08-06 Determination de la concentration d'analyte a l'aide de deux substances de marquage Pending EP0318491A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868619206A GB8619206D0 (en) 1986-08-06 1986-08-06 Fluorometric determination of analyte concentration
GB8619206 1986-08-06

Publications (1)

Publication Number Publication Date
EP0318491A1 true EP0318491A1 (fr) 1989-06-07

Family

ID=10602323

Family Applications (2)

Application Number Title Priority Date Filing Date
EP87905234A Pending EP0318491A1 (fr) 1986-08-06 1987-08-06 Determination de la concentration d'analyte a l'aide de deux substances de marquage
EP87306995A Expired - Lifetime EP0271974B1 (fr) 1986-08-06 1987-08-06 Détermination de la concentration d'analyte utilisant deux étiquettes

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP87306995A Expired - Lifetime EP0271974B1 (fr) 1986-08-06 1987-08-06 Détermination de la concentration d'analyte utilisant deux étiquettes

Country Status (8)

Country Link
EP (2) EP0318491A1 (fr)
KR (1) KR960010696B1 (fr)
CA (1) CA1284620C (fr)
DE (1) DE3784465T2 (fr)
ES (1) ES2039444T3 (fr)
GB (1) GB8619206D0 (fr)
GR (1) GR3007803T3 (fr)
ZA (1) ZA875825B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2233450B (en) * 1989-06-24 1993-06-30 Univ Wales Medicine Detecting or quantifing multiple analytes with luminescent reagents
JP2683172B2 (ja) * 1991-10-01 1997-11-26 キヤノン株式会社 検体測定方法及び検体測定装置
EP0660935B1 (fr) * 1992-08-03 2000-05-24 Gec-Marconi Limited Detection immunologique au moyen de deux marqueurs detectables
JP2000512744A (ja) * 1996-05-16 2000-09-26 アフィメトリックス，インコーポレイテッド 標識材料を検出するシステムおよび方法
GB9621256D0 (en) * 1996-10-11 1996-11-27 Xenova Ltd Assay
GB2335038B (en) * 1996-10-11 2001-03-07 Xenova Ltd Double label immunoassay
US7157234B2 (en) * 1997-10-24 2007-01-02 Beckman Coulter, Inc. Detection of very low quantities of analyte bound to a solid phase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341957A (en) * 1975-11-26 1982-07-27 Analytical Radiation Corporation Fluorescent antibody composition for immunofluorometric assay
CA1111762A (fr) * 1977-12-28 1981-11-03 David S. Frank Chelate de terre rare fluorescent dans des particules de latex polymerique
US4381291A (en) * 1979-02-23 1983-04-26 Ab Fortia Measurement of free ligands
WO1980002076A1 (fr) * 1979-03-19 1980-10-02 Diagnostic Techn Int Inc Essais immunologiques a double marquage
US4366143A (en) * 1979-09-24 1982-12-28 Amersham International Public Limited Company Assay for the free portion of substances in biological fluids
JPH0664059B2 (ja) * 1982-08-27 1994-08-22 マルティライト リミティド 被検体の濃度の測定方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8801058A1 *

Also Published As

Publication number Publication date
DE3784465T2 (de) 1993-06-17
CA1284620C (fr) 1991-06-04
KR960010696B1 (ko) 1996-08-07
EP0271974B1 (fr) 1993-03-03
GB8619206D0 (en) 1986-09-17
EP0271974A1 (fr) 1988-06-22
DE3784465D1 (de) 1993-04-08
ZA875825B (en) 1988-04-27
ES2039444T3 (es) 1993-10-01
KR880701885A (ko) 1988-11-05
GR3007803T3 (fr) 1993-08-31

Similar Documents

Publication Publication Date Title
US5171695A (en) Determination of analyte concentration using two labelling markers
US4626513A (en) Method and apparatus for ligand detection
Ekins et al. Multianalyte microspot immunoassay--microanalytical" compact disk" of the future
CA1334278C (fr) Mesure des concentrations ambiantes de plusieurs substances a analyser
CA1179940A (fr) Systeme pour le titrage des ligands en phase solide
US8956823B2 (en) Anti-antibody reagent
CA1137410A (fr) Epreuve immunologique avec double marqueur
NO164622B (no) Binaer immunometrisk partikkelbasert metode for maaling av spesifikke serum-antigener ved hjelp av vaeskestroemsmikrofotometri og et ferdigpreparert maaloppsett derav.
JPH0654317B2 (ja) イムノアッセイ装置
US5389523A (en) Liposome immunoanalysis by flow injection assay
US6103486A (en) Process and test kit for determining free active compounds in biological fluids
Ekins et al. Developing multianalyte assays
Ekins Immunoassay design and optimization
EP0968422B1 (fr) Amelioration des resultats des dosages d'immunodetection grace a l'emploi de plusieurs traceurs
US4786606A (en) Solid phase system for ligand assay
EP0271974B1 (fr) Détermination de la concentration d'analyte utilisant deux étiquettes
US4307071A (en) Analytical reagent and method
Perez-Bendito et al. Direct stopped-flow fluorescence polarization immunoassay of abused drugs and their metabolites in urine
US4618485A (en) Kinetic radioimmunoassay test method and device
Tommasi et al. On-line computer analysis of chemiluminescent reactions, with application to a luminescent immunoassay for free cortisol in urine.
JPH10221341A (ja) 体液中の遊離リガンドの測定方法
MENONNA et al. Rapid fluorometric assay for cerebrospinal fluid immunoglobulin G
Fogg et al. Determination of drugs in biological materials
Pimputkar et al. Radioimmunoassay kit evaluation and selection
Miyai et al. Comparison of Radioimmunoassay with Enzyme-and Fluorescence-Immunoassays

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19890128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EKINS, ROGER PHILIP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 19900117

XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 87306995.9/0271974 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 03.05.90.